Knight Therapeutics (GUD) Stock Overview
Focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GUD from our risk checks.
GUD Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$6.01 |
| 52 Week High | CA$6.55 |
| 52 Week Low | CA$5.11 |
| Beta | 0.11 |
| 1 Month Change | -2.12% |
| 3 Month Change | -4.60% |
| 1 Year Change | 16.02% |
| 3 Year Change | 15.80% |
| 5 Year Change | 8.48% |
| Change since IPO | 56.92% |
Recent News & Updates
Recent updates
Knight Therapeutics' (TSE:GUD) Solid Profits Have Weak Fundamentals
May 16
Paladin Acquisition And New Launches Will Expand Market Presence
Acquisitions and expanded partnerships bolster Knight's Canadian and oncology revenue, enhancing stability and growth prospects.Knight Therapeutics Inc.'s (TSE:GUD) Popularity With Investors Is Clear
Mar 18Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 09Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 28Shareholder Returns
| GUD | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 1.2% | 34.3% | 0.8% |
| 1Y | 16.0% | 36.9% | 23.1% |
Return vs Industry: GUD underperformed the Canadian Pharmaceuticals industry which returned 36.9% over the past year.
Return vs Market: GUD underperformed the Canadian Market which returned 23.1% over the past year.
Price Volatility
| GUD volatility | |
|---|---|
| GUD Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 14.1% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 20.4% |
| 10% least volatile stocks in CA Market | 3.2% |
Stable Share Price: GUD has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: GUD's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 745 | Samira Sakhia | www.knighttx.com |
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease.
Knight Therapeutics Inc. Fundamentals Summary
| GUD fundamental statistics | |
|---|---|
| Market cap | CA$602.69m |
| Earnings (TTM) | -CA$3.49m |
| Revenue (TTM) | CA$413.85m |
Is GUD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUD income statement (TTM) | |
|---|---|
| Revenue | CA$413.85m |
| Cost of Revenue | CA$237.99m |
| Gross Profit | CA$175.86m |
| Other Expenses | CA$179.35m |
| Earnings | -CA$3.49m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 42.49% |
| Net Profit Margin | -0.84% |
| Debt/Equity Ratio | 12.6% |
How did GUD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 23:44 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Knight Therapeutics Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | Beacon Securities Limited |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |